Literature DB >> 1270239

Flutamide. Mechanism of action of a new nonsteroidal antiandrogen.

G Sufrin, D S Coffey.   

Abstract

Flutamide is a new nonsteroidal antiandrogen useful in the treatment of prostatic carcinoma. The mechanism of action of this compound was investigated using the sex accessory tissue of the male rat. Flutamide was found to block the action of both endogenous and exogenous testosterone and, in addition, to be a potent inhibitor of testosterone-stimulated prostatic DNA synthesis. Moreover, it is capable of inhibiting prostatic nuclear uptake of androgen. Electron microscopic observations further confirm the antiandrogenic properties of flutamide.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 1270239

Source DB:  PubMed          Journal:  Invest Urol        ISSN： 0021-0005


  11 in total

Review 1.  Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.

Authors:  Christopher Foley; Nicholas Mitsiades
Journal:  Horm Cancer       Date:  2016-01-04       Impact factor: 3.869

2.  Androgen receptor transcriptionally regulates μ-opioid receptor expression in rat trigeminal ganglia.

Authors:  Ki Seok Lee; Youping Zhang; Jamila Asgar; Q-Schick Auh; Man-Kyo Chung; Jin Y Ro
Journal:  Neuroscience       Date:  2016-06-16       Impact factor: 3.590

3.  Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.

Authors:  David T Hoang; Lei Gu; Zhiyong Liao; Feng Shen; Pooja G Talati; Mateusz Koptyra; Shyh-Han Tan; Elyse Ellsworth; Shilpa Gupta; Heather Montie; Ayush Dagvadorj; Saija Savolainen; Benjamin Leiby; Tuomas Mirtti; Diane E Merry; Marja T Nevalainen
Journal:  Mol Cancer Ther       Date:  2014-12-31       Impact factor: 6.261

4.  Research Resource: Hormones, Genes, and Athleticism: Effect of Androgens on the Avian Muscular Transcriptome.

Authors:  Matthew J Fuxjager; Jae-Hyung Lee; Tak-Ming Chan; Jae Hoon Bahn; Jenifer G Chew; Xinshu Xiao; Barney A Schlinger
Journal:  Mol Endocrinol       Date:  2016-01-08

5.  Ubiquitylation of epsilon-COP by PIRH2 and regulation of the secretion of PSA.

Authors:  Satoru Maruyama; Naoto Miyajima; Miyuki Bohgaki; Tadasuke Tsukiyama; Masahiko Shigemura; Katsuya Nonomura; Shigetsugu Hatakeyama
Journal:  Mol Cell Biochem       Date:  2007-08-25       Impact factor: 3.396

6.  P2-purinergic receptor agonists inhibit the growth of androgen-independent prostate carcinoma cells.

Authors:  W G Fang; F Pirnia; Y J Bang; C E Myers; J B Trepel
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

7.  Contribution of Endogenous Spinal Endomorphin 2 to Intrathecal Opioid Antinociception in Rats Is Agonist Dependent and Sexually Dimorphic.

Authors:  Arjun Kumar; Nai-Jiang Liu; Priyanka A Madia; Alan R Gintzler
Journal:  J Pain       Date:  2015-09-02       Impact factor: 5.820

8.  Nonsteroidal antiestrogens and partial estrogens with prostatic tumor inhibiting activity.

Authors:  M R Schneider; R W Hartmann; F Sinowatz; W Amselgruber
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

9.  Polyacrylamide-punicic acid conjugate-based micelles for flutamide delivery in PC3 cells of prostate cancer: synthesis, characterisation and cytotoxicity studies.

Authors:  Razieh Mirsafaei; Jaleh Varshosaz
Journal:  IET Nanobiotechnol       Date:  2020-07       Impact factor: 1.847

10.  Mitochondrial respiratory function induces endogenous hypoxia.

Authors:  Sara Prior; Ara Kim; Toshitada Yoshihara; Seiji Tobita; Toshiyuki Takeuchi; Masahiro Higuchi
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.